The Company That Maps Every Doctor on Earth

Ask a pharmaceutical company how it decides which physician should lead a clinical trial, and you may get an uncomfortable answer: for decades, a lot of it came down to who someone happened to know. H1, a New York healthcare-data company founded in 2017, was built on the premise that the answer should come from data instead.

The company's name is a small in-joke for anyone who has sat through a statistics class. "H1" is the symbol for the alternative hypothesis - the one you accept when the evidence says a real effect exists. It is a fitting label for a business whose entire product is evidence: who practices medicine, what they publish, which trials they run, and which patients they treat. Co-founders Ariel Katz and Ian Sax launched it as "H1 Insights," and the ambition has stayed constant even as the product line has multiplied.

At its core, H1 aggregates the fragmented record of global healthcare into one searchable platform. That record is enormous and famously disorganized: roughly 160 million peer-reviewed publications, some 350,000 clinical trials, and around 8 billion medical claims, alongside provider directories and prescriber data. Individually, none of these datasets is secret. The hard part - the part H1 sells - is connecting them so that a single question ("who is the right doctor for this?") returns a usable answer.

A search engine for medical expertise

H1 describes its mission as "creating a healthier future by making healthcare information and evidence-based medicine accessible to everyone globally." In practice, the platform lets a life-sciences team start with a criterion - a disease area, a molecule, a geography, a patient population - and surface the healthcare professionals, research sites and prescribers who match. A medical affairs team uses it to map key opinion leaders. A clinical operations team uses it to choose trial sites and investigators. A commercial team uses it to find the physicians most likely to prescribe a therapy once it launches.

That is a bold claim, and it is worth reading it as a statement of intent rather than a literal audit. But it captures the shape of the company. H1 is not trying to be a niche tool for one department; it is trying to be the reference layer that every healthcare stakeholder consults when the question involves a person - a physician, a researcher, a prescriber, or an entire provider network.

Pharma, payers, and now provider networks

H1's customers cluster at the industrial end of healthcare. The company reports that roughly 200 organizations across six continents use the platform, and that its customer base includes about 85% of the top 20 pharmaceutical companies and nine of the ten largest US payers. Publicly named customers include Novartis, Eli Lilly, Sanofi, AstraZeneca, Gilead Sciences, Johnson & Johnson, Centene, and the Michael J. Fox Foundation.

The mix matters. Selling to pharma means selling into medical affairs, clinical development and commercial teams - each with its own data appetite. Selling to payers, which H1 accelerated with its 2025 acquisition of Ribbon Health, means something different: keeping provider directories accurate so that patients who look up a doctor actually reach one who is in-network and accepting patients. By H1's account, an estimated 20 to 25 million Americans a year touch the Ribbon-built data when they search for a provider.

The expensive cost of guessing

The problems H1 targets are unglamorous but costly. Clinical trials routinely run over budget and behind schedule, and a major reason is site selection: pick investigators and hospitals that can't enroll the right patients, and a study stalls. Drug launches misfire when companies can't identify the clinicians who treat the relevant condition. And provider directories - the humble lists insurers are required to maintain - are notoriously riddled with errors, sending patients to doctors who have moved, retired, or stopped taking their plan.

Each of these is, underneath, the same problem: decisions made without good data about who practices medicine and where. H1's pitch is that turning those guesses into queries saves time, money, and - in the case of trials and directories - patient outcomes. It is a data-plumbing business dressed in the language of healthcare access, and both descriptions are accurate.

One platform, many front doors

H1 has organized its platform into suites aimed at different buyers. The through-line is that they all draw on the same underlying healthcare graph.

The 2024 arrival of GenosAI is the clearest signal of where the company is heading. Rather than bolt a chatbot onto a marketing page, H1 embedded conversational AI directly into the workflow where clinical feasibility teams design trials - producing the slides, diversity plans and site "biobooks" those teams would otherwise assemble by hand. It is AI aimed at a specific, expensive task rather than AI as a demo.

Subscriptions on top of data

H1 runs a business-to-business subscription model. Customers license access to the platform and its intelligence products, with enterprise contracts spanning medical, clinical, commercial and provider-data use cases, plus data-stream and master-data-management services for teams that want to pipe H1's data into their own systems. The economics of the model favor breadth: the same underlying data can be sold to a drugmaker's medical team, its commercial team, and - after the Ribbon deal - to the insurer on the other side of the market.

From Y Combinator to a $773M valuation

H1 went through Y Combinator's Winter 2020 batch and then raised quickly: a $12.9M Series A in April 2020, a $58M Series B that December, and a $100M Series C led by Altimeter Capital in November 2021. In June 2022 - as venture markets seized up - it added a $33M extension, bringing the Series C to $123M at a reported $773M valuation. Katz framed the flat extension bluntly.

Competing on connection, not collection

H1 does not operate in an empty field. Definitive Healthcare, IQVIA, Veeva Systems, Komodo Health, Clarivate and Doximity all sell slices of the same market - HCP data, real-world evidence, or provider directories. Several are larger and older. What H1 argues sets it apart is integration: rather than owning one dataset, it stitches publications, trial records, claims and directories into a single graph, then layers search and AI on top. The Faculty Opinions and Carevoyance acquisitions in 2021-2022, and Ribbon Health in 2025, are all moves to widen that graph rather than deepen a single silo.

Whether that integration advantage holds is the open question of the business. Incumbents have scale and entrenched contracts; H1's bet is that customers would rather ask one platform a question than assemble the answer from five vendors. The addition of a former FDA Commissioner to its board in 2025, announced alongside the Ribbon acquisition and a product roadmap, reads as an effort to pair that technical pitch with regulatory credibility.

The reference layer of healthcare

Step back and H1 occupies a specific seat in the healthcare economy: the layer that answers "who." Drug developers, marketers, insurers and digital-health startups all need a trustworthy map of healthcare professionals, and each has historically built or bought a partial one. H1's ambition is to be the shared map they all reference - useful precisely because it is not tied to any single workflow. The plumbing, in other words, is the point. If the company succeeds, most people will never know its name, even as its data quietly shapes which trials run, which drugs reach which doctors, and whether a patient's search for a physician ends at someone who can actually help.